Most important in brief
- For EGFR and ALK, the main tablets are on the list; for lung cancer without these changes, immunotherapy with pembrolizumab or atezolizumab.
- No medicine for KRAS G12C, ROS1, RET, MET, NTRK or HER2 is on the list.
- Three doctors at one of the seven named hospitals propose the treatment; the RFZO commission approves it.
What applies now
Lists B and C of the RFZO health insurance fund, valid from 11 July 2026 · List C (PDF), List B (PDF) · checked on 16 November 2026
| Test result | Medicine | What for (simplified) |
|---|---|---|
| EGFR | osimertinib | First treatment for advanced NSCLC with an EGFR mutation; with T790M after an earlier EGFR tablet; after complete surgery (stage IB–IIIA, exon 19 or L858R). |
| EGFR | gefitinib, erlotinib, afatinib | First treatment, stage IIIb/IV, good general condition. Erlotinib also later in adenocarcinoma. |
| ALK | alectinib, brigatinib | First treatment for advanced ALK-positive NSCLC. |
| no EGFR or ALK | pembrolizumab | First treatment: alone if PD-L1 is 50% or more, with chemotherapy if PD-L1 is lower. A few cycles first, then continued only if it works. |
| no EGFR or ALK | atezolizumab | First treatment alone if PD-L1 is high, or with chemotherapy; also after chemotherapy. |
| Chemotherapy | carboplatin, cisplatin, docetaxel, paclitaxel, gemcitabine, vinorelbine, pemetrexed | Lists B and C. Everything on these lists is fully paid by the fund. |
How to get the treatment
Three doctors from one of the hospitals below propose the treatment, and the RFZO commission approves it. The list names these hospitals:
- Institut za onkologiju i radiologiju Srbije (Beograd)
- Klinika za pulmologiju, UKC Srbije (Beograd)
- KBC Bežanijska kosa (Beograd)
- Vojnomedicinska akademija (Beograd)
- Institut za plućne bolesti Vojvodine (Sremska Kamenica)
- Klinika za plućne bolesti, UKC Niš
- UKC Kragujevac
Not on the list
Lorlatinib, crizotinib and durvalumab; no medicine against KRAS G12C, ROS1, RET, MET, NTRK or HER2. Dabrafenib and trametinib are listed for melanoma only.
What is not publicly known
A new regulation from July 2026 may come with newer tables. Whether biomarker tests are always paid is not stated in these lists.
What this means for you
If you are treated in Serbia and your report shows EGFR or ALK, the main tablets are paid. Without these changes it is usually immunotherapy. A team of doctors at one of the named hospitals applies; ask whether your hospital is one of them.
For KRAS G12C, ROS1 and the rarer changes, no medicine is on the list. Ask your care team what other ways there are.